Surgical management of metastatic gastrointestinal stromal tumour
Yvonne Schrage(The Netherlands Cancer Institute), Jos A. van der Hage(Leiden University Medical Center), Myles Smith(Royal Marsden NHS Foundation Trust), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Christina Messiou(Institute of Cancer Research), Sylvie Bonvalot(Dana-Farber Cancer Institute), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Dimitri Tzanis(Université Paris Cité), Henk H. Hartgrink(Leiden University Medical Center), Vincent Servois(Université Paris Sciences et Lettres)
Cited by 22
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k